Melanotan I (Afamelanotide): Linear α-MSH Design, MC1R Structural Pharmacology, and Analytical Verification — A 2026 Research Guide

Melanotan I is the rare research peptide with a complete paper trail. It began as a 1980 structure–activity experiment at the University of Arizona, became the reference agonist most of melanocortin pharmacology was built on, and in 2019 became the only molecule in its class to hold a marketing authorization anywhere — approved as afamelanotide for a rare photosensitivity disorder. In 2021 it was captured in a cryo-EM structure bound to its receptor, so the binding pose researchers spent forty years inferring from analog series is now deposited in the Protein Data Bank. Very few compounds in the research market have that depth of characterization behind them. Fewer still are as easy to confuse with a structurally adjacent molecule sold under a nearly identical name. This guide covers the molecular profile, the receptor-level mechanism, the published record, and what a certificate of analysis on this peptide has to demonstrate.

The information below describes in-vitro and preclinical laboratory research only. It is not medical guidance, and none of the findings described here establish safety or efficacy in humans.

Section 1 — Molecular Profile

Melanotan I is a synthetic linear tridecapeptide analog of α-melanocyte-stimulating hormone (α-MSH). Unlike Melanotan II, it retains the full 13-residue length of the native hormone and is not cyclized; its potency comes from two point substitutions rather than from conformational constraint.

Key identifiers used in the literature and on analytical documentation:

• Compound name: Melanotan I; MT-1; afamelanotide; NDP-α-MSH; NDP-MSH; [Nle4, D-Phe7]-α-MSH
• CAS number: 75921-69-6 (free base); 1566590-77-9 (acetate salt)
• Molecular formula: C78H111N21O19
• Molecular weight: approximately 1,646.9 Da
• Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
• Structure class: linear tridecapeptide; pan-melanocortin agonist with high MC1R affinity
• Modifications: N-terminal acetylation, C-terminal amidation, norleucine substitution at position 4, D-phenylalanine inversion at position 7

The naming situation deserves a sentence of its own, because it is a genuine source of error in sourcing and in literature searching. Melanotan I, afamelanotide, and NDP-α-MSH are three names for the same molecule — the trade and INN names attached to the pharmaceutical product, and the medicinal-chemistry designation used in four decades of primary literature. Searching one name and not the others will return a small fraction of the available record. Separately, Melanotan II is a different compound entirely: a cyclic heptapeptide of roughly 1,024 Da with a different sequence, a different selectivity profile, and a different analytical signature. The names differ by one character; the molecules differ by 622 daltons.

Two substitutions define the design. Methionine at position 4 is replaced by norleucine, removing the oxidation-labile thioether that made native α-MSH difficult to handle and store. L-phenylalanine at position 7 is inverted to D-phenylalanine, which stabilizes the bioactive β-turn geometry of the His-Phe-Arg-Trp message sequence and makes the peptide resistant to the serum proteases that degrade the native hormone within minutes. Sawyer and colleagues reported both effects in their 1980 PNAS paper, measuring roughly 26-fold greater potency than α-MSH in a melanoma adenylate cyclase assay along with the prolonged activity that gave the analog its early “ultralong-acting melanotropin” description.

Handling consequences follow from the composition. Both termini are capped, blocking exopeptidase attack. The single tryptophan at position 9 and the tyrosine at position 2 are the two most oxidation-prone residues in the standard set, and make the molecule photolabile in solution. The basic residues (Arg8, Lys11) mean lyophilized material carries a counterion load, typically acetate or trifluoroacetate depending on purification route, so gross vial weight and net peptide content are not the same figure. Standard practice is storage at −20 °C or below, desiccated and protected from light, with stock aliquoted to avoid freeze-thaw cycling.

Section 2 — Mechanism

All activity described here is at the receptor and pathway level, in defined experimental systems.

The receptor family. The melanocortin system comprises five G protein-coupled receptors, MC1R through MC5R, signalling principally through Gs and adenylyl cyclase to raise intracellular cAMP. Tissue distribution differs: MC1R on melanocytes and immune cells, MC2R as the ACTH-selective adrenal receptor, MC3R and MC4R predominantly central, MC5R in exocrine tissue. NDP-α-MSH is reported to have nanomolar efficacy at every subtype except MC2R, which does not recognize α-MSH-derived ligands. In practice its highest-affinity and best-characterized interaction is at MC1R, which is why it functions as the field’s reference MC1R agonist even though it is not subtype-selective.

The MC1R cascade. The canonical in-vitro pathway is the melanogenesis cascade in cultured melanocytes. MC1R activation raises cAMP; cAMP activates protein kinase A; PKA phosphorylates CREB; CREB drives transcription of MITF, the master regulator of the melanocyte differentiation program. MITF in turn drives expression of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), dopachrome tautomerase (DCT), and PMEL. Tyrosinase is the rate-limiting enzyme of the pathway, so tyrosinase activity in cultured cells is the standard functional readout for MC1R agonism. In an in-vitro context, “melanogenesis” means transcript and enzyme-activity changes in a dish — not any organismal outcome.

What the structures showed. In 2021 Ma and colleagues published cryo-EM structures of the human MC1R–Gs complex bound to α-MSH, to afamelanotide, and to the synthetic agonist SHU9119, deposited as PDB entries 7F4D, 7F4F/7F4H, and 7F4I. The structures resolved the orthosteric pocket that engages the conserved HFRW motif and identified an unexpected requirement: a calcium ion acts as a cofactor bridging the ligand and the receptor, coordinated by acidic receptor residues and the ligand’s own carboxylate. The same work described a specific mode of Gs coupling and direct receptor–Gβ contacts not previously observed in this family. For assay design this is not an abstraction — divalent cation content in buffer is a variable that can move apparent affinity, and it belongs in the methods section rather than in the assumptions.

Beyond pigmentation. MC1R is also expressed on keratinocytes and on cells of the innate immune system, and the receptor has been studied for signalling roles independent of melanin synthesis. Published in-vitro work has examined α-MSH/MC1R signalling in relation to nucleotide excision repair components and to Nrf2-linked antioxidant gene expression in cultured keratinocytes and melanocytes, and a substantial preclinical literature has examined MC1R agonism in models of inflammatory signalling. These are pathways the receptor has been studied for; the mechanistic detail is better established than any downstream claim, and nothing in this body of work speaks to human outcomes.

Throughout the literature these are mechanisms MT-1 has been studied for and researched for — melanocortin receptor agonism, cAMP/PKA/CREB/MITF pathway activation in melanocyte culture, calcium-dependent orthosteric binding at MC1R, and use as a reference agonist in preclinical receptor pharmacology — not demonstrated clinical effects outside its single approved indication.

Section 3 — Preclinical and In-Vitro Research Data

The MT-1 record is unusually deep because the compound has served three separate roles: original design target, universal reference agonist, and eventually a clinical-stage molecule.

The originating pharmacology. Sawyer et al. (1980) established the core result in PNAS: the Nle4/D-Phe7 analog was substantially more potent than α-MSH in melanoma adenylate cyclase assays, resistant to serum enzymatic degradation, and active in frog and lizard skin bioassays with a duration that outlasted the native hormone by orders of magnitude. The prolonged-activity finding is what made the analog useful — a reagent that survives an experiment is worth more than one that degrades mid-assay.

Irreversible tyrosinase activation. A 1986 study characterized NDP-α-MSH as a melanotropin that “irreversibly” activates melanoma tyrosinase: after the peptide was washed out of the incubation medium, stimulatory effects on tyrosinase activity persisted for up to 72 hours, in contrast to the rapidly reversible response to native α-MSH. Subsequent work reported the peptide to be roughly 100-fold more effective than α-MSH at stimulating tyrosinase in melanoma cell culture. This washout behaviour is a practical assay consideration, not a curiosity — a compound whose effect outlives its presence in the well will confound any experiment designed around reversibility.

Human melanoma cell work. A 1996 study reported that NDP-α-MSH stimulated tyrosinase activity while inhibiting proliferation in human melanoma cell lines, a dissociation between the differentiation and growth programs that has been examined repeatedly since. Fragment work in the late 1980s — including Ac-[Nle4, D-Phe7]α-MSH4-11-NH2 in B16 F1 murine melanoma cells — mapped which portion of the sequence carried the binding and metabolic behaviour, contributing to the identification of the tetrapeptide message sequence that later structural work confirmed.

Reference-ligand status. Across the melanocortin literature NDP-α-MSH is the standard comparator. It is the agonist used to define 100% response in cAMP accumulation assays, the radiolabelled or fluorescently tagged probe in competition binding, and the positive control against which selective analogs are benchmarked. Structural work on MC4R, including the 2011 characterization of MC4R–NDP-MSH interactions and the 2021 cryo-EM structures of active MC4R–Gs complexes with NDP-α-MSH and setmelanotide, used it for the same reason: it binds well enough and stably enough to be resolved.

Clinical-stage literature. Afamelanotide was evaluated in two Phase 3 randomized, double-blind, placebo-controlled trials in erythropoietic protoporphyria, published by Langendonk and colleagues in the New England Journal of Medicine in 2015, and received FDA approval in October 2019 for a narrow indication in adults with EPP. This clinical record exists and is worth knowing about, for two reasons: it means the molecule’s pharmacology has been examined under regulatory scrutiny, and it means the approved product is a specific controlled-release implant formulation manufactured to pharmaceutical standards. Research-grade lyophilized MT-1 is not that product, is not equivalent to it, and carries none of its regulatory status. The published clinical findings pertain to the approved drug under medical supervision and say nothing about laboratory research material.

Two limitations should be stated plainly. First, outside the single approved indication this is a preclinical and in-vitro record; nothing in it establishes human safety or efficacy for any other purpose. Second, published reviews of chronic melanocortin-1 receptor activation, including a 2024 overview in the British Journal of Pharmacology, note that the long-term consequences of sustained MC1R agonism remain incompletely characterized even at the preclinical level. That is an open scientific question.

Section 4 — Published Literature

The following are real, published papers anchoring the MT-1 record. Researchers should consult the primary sources rather than relying on summaries.

• Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME (1980). “4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity.” Proceedings of the National Academy of Sciences USA 77(10):5754–5758. PMID 6777774. The originating paper.
• Marwan MM, Abdel Malek ZA, Kreutzfeld KL, et al. (1986). “[Nle4, D-Phe7]-α-MSH: a superpotent melanotropin that ‘irreversibly’ activates melanoma tyrosinase.” Molecular and Cellular Endocrinology. PMID 3009169.
• Sahm UG, Olivier GW, Branch SK, et al. (1987/1996 series). Fragment and binding studies including “Biological activity, binding, and metabolic fate of Ac-[Nle4, D-Phe7]α-MSH4-11NH2 with the F1 variant of B16 melanoma cells.” PMID 3110178.
• “The melanotropic peptide, [Nle4, D-Phe7] α-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation” (1996). PMID 8789740.
• Dorr RT, Ertl G, Levine N, et al. (2005). “Effect of Melanotan, [Nle4, D-Phe7]-α-MSH, on melanin synthesis in humans with MC1R variant alleles.” PMID 16293341. Published clinical pharmacology study.
• Chen KY, Muniyappa R, Abel BS, et al. (2011). “Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.” PMC3101337.
• Langendonk JG, Balwani M, Bottomley SS, et al. (2015). “Afamelanotide for erythropoietic protoporphyria.” New England Journal of Medicine 373(1):48–59. The Phase 3 record for the approved product.
• Ma S, Yin Y, Wu H, et al. (2021). “Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor.” Cell Research. PDB entries 7F4D, 7F4F, 7F4H, 7F4I. Cryo-EM structures of MC1R–Gs with α-MSH, afamelanotide, and SHU9119.
• Israeli H, Degtjarik O, Fierro F, et al. (2021). “Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide.” Science.
• “MC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair” (2018). International Journal of Molecular Sciences. PMID 30205559.
• “Probing the role of melanocortin type 1 receptor agonists in diverse immunological diseases” (2018). PMC6339910.
• “Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects” (2023). International Journal of Molecular Sciences. PMC10418475. Current MC1R pharmacology review.
• “An overview of benefits and risks of chronic melanocortin-1 receptor activation” (2024). British Journal of Pharmacology. PMC11664455.

Together these span the 1980 design origin, the classical melanoma cell-culture pharmacology, the clinical development record, the 2021 structural biology, and current receptor reviews — an unusually complete arc for a compound available as a research peptide.

Section 5 — Research Applications

In laboratory settings, MT-1 appears principally as the reference melanocortin agonist. Reported in-vitro applications include use as the full-agonist positive control in MC1R, MC3R, MC4R, and MC5R binding and cAMP accumulation assays in transfected CHO or HEK cell lines; as the agonist arm in tyrosinase-activity and MITF/TYR/TYRP1 expression assays in cultured human melanocytes and B16 murine melanoma cells; as the labelled or unlabelled competitor in radioligand and fluorescence-polarization binding studies; as the reference ligand in structural biology, where its stable binding pose makes it the agonist of choice for cryo-EM complexes; and as the benchmark against which subtype-selective analogs and antagonists such as SHU9119 are calibrated.

Assay-design variables worth attention. Receptor expression level strongly influences apparent potency in cAMP assays, so EC50 values are not comparable across cell lines without stating receptor density. The 2021 structural finding that calcium participates directly in orthosteric binding means buffer divalent cation content is a real experimental variable at MC1R and should be specified rather than inherited from a generic protocol. The tryptophan and tyrosine residues make the peptide photolabile and oxidation-sensitive in solution. The washout persistence reported in the 1986 tyrosinase work means reversibility cannot be assumed in melanocyte assays — a wash step does not necessarily return the system to baseline. And because MC1R signalling converges on cAMP, any assay run with phosphodiesterase inhibitors present will report a different dynamic range than one run without them; the condition needs to be reported, not assumed.

Section 6 — How to Evaluate a Source

MT-1 presents a specific and unusually tractable analytical problem: the two most likely failure modes both produce material that looks correct on a label and wrong on a mass spectrum.

The first is substitution or cross-contamination with Melanotan II. The names differ by one character, the compounds are often synthesized and filled in the same facilities, and at 1,646.9 Da versus roughly 1,024.2 Da they are trivially distinguishable by mass spectrometry — but only if someone actually runs the identity test on the lot in question. A COA that reports purity without reporting observed mass does not answer this question.

The second is oxidation and photodegradation. Tryptophan and tyrosine are the two most oxidation-prone residues in the standard set, and this peptide has one of each. Oxidized species appear as characteristic +16 Da satellites and typically resolve as shoulders adjacent to the main peak on a reversed-phase trace. A purity percentage stated without a chromatogram cannot show you whether the reported impurity is a synthesis-related truncation, a diastereomer from incomplete D-Phe incorporation, or an oxidation product that accumulated in storage.

What the analytical package needs to show:

• Purity by HPLC, with a stated percentage and the chromatogram. For a 13-residue linear peptide the relevant impurity classes are deletion sequences, incomplete acetylation or amidation, and oxidation products. A bare “≥99%” without a trace tells you nothing about which 1% is present.
• Identity by LC-MS, with an observed mass consistent with approximately 1,646.9 Da for the free base. This is the test that distinguishes MT-1 from MT-2, confirms both terminal modifications, and surfaces oxidized species.
• Endotoxin by USP <85> LAL, with an actual figure rather than a “meets specification” checkbox.
• Heavy metals by ICP-MS.
• Net peptide content and counterion, disclosed. Acetate and trifluoroacetate salts carry meaningfully different mass burdens on a 1,647 Da peptide, and TFA itself is biologically active in some cell assays at concentrations that survive lyophilization.
• Lot-specificity. The COA must correspond to the exact batch shipped, be dated, and name the accredited laboratory that performed the testing. A generic COA reused across lots is a marketing document.

Market pricing context: research-grade MT-1 at the 10 mg scale is commonly listed in roughly the $16–$40 range at the low end of the market and roughly $40–$95 at vendors claiming independent third-party testing, with bulk pricing below both. A 13-residue linear peptide with two terminal caps and one D-amino acid is a routine solid-phase synthesis, so cost differences across that range reflect testing and margin far more than they reflect synthesis difficulty. Price is a weak signal here. The differentiator is whether a named accredited laboratory tested the specific lot in your hand and published the chromatogram and the mass spectrum alongside it.

Regulatory note: on 15 April 2026 the FDA announced the removal of twelve peptide bulk substances from Category 2 and scheduled Pharmacy Compounding Advisory Committee meetings to consider peptides for the 503A bulk drug substances list; the July 2026 PCAC meeting addressed the first seven substances. Afamelanotide occupies a distinct position from most compounds in this space because it holds an approved NDA for a narrow indication, which shapes how compounded and research-use material is treated under Sections 503A and 503B. The FDA has also issued letters to vendors whose “research use only” advertising indicated intended human use. None of that changes the status of material genuinely supplied for laboratory work — but it does mean documentation and labelling discipline are not optional in 2026.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

On a compound where the primary risk is confusion with a 622-dalton-lighter molecule of the same name family, the identity test is the whole argument. A mass spectrum on the actual lot settles in one measurement what no amount of label copy can.

Founding batches are documented end to end, and full analytical data files are available per lot. You can review current documentation in the COA library, read the underlying methodology on the verification standard page, or browse the full catalog in the shop.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.